This article is more than 5 years old. Information may no longer be current.
Diquafosol tetrasodium drops more effective than conventional therapy for LASIK-associated dry eye
Click Here to Manage Email Alerts
Treatment of LASIK-associated dry eye syndrome with diquafosol tetrasodium eye drops demonstrated better efficacy than conventional therapy, according to researchers.
A prospective study included 30 eyes of 15 patients with dry eye symptoms that persisted for 12 months following LASIK surgery, with no improvement after treatment with artificial tears and sodium hyaluronate. Patients were given 3% disquafosol tetrasodium (DSQ) eye drops six times a day for 12 weeks. The researchers evaluated best corrected visual acuity, tear secretion, tear break-up time, and fluorescein and lissamine green staining scores on the cornea and conjunctiva before treatment and again at 1, 4 and 12 weeks after the added treatment.
Although BCVA and tear secretion did not change, fluorescein and lissamine green staining scores demonstrated significant improvements from before treatment to 12 weeks post-treatment (P < .01). Tear break-up time improved significantly at 1, 4 and 12 weeks after treatment (P = .007, P < .001 and P < .001, respectively); however, this measurement did not return to normal levels of 10 seconds or less in any of the eyes by 12 weeks, according to the researchers.
Fatigue, dryness, grittiness, discomfort, difficulty reading, discomfort in dry areas and blurred vision also improved, and no complications or adverse effects were reported with regard to DSQ treatment.
Disclosure: The authors have no relevant financial disclosures.
Click Here to Manage Email Alerts